國立虎尾科技大學 |

A Chemical Biology Approach to the Cell Type Selective Killing of Glioblastoma Tumor Cells.

紀錄類型:	書目-語言資料,手稿 : Monograph/item
正題名/作者:	A Chemical Biology Approach to the Cell Type Selective Killing of Glioblastoma Tumor Cells./
作者:	West, Thomas.
面頁冊數:	1 online resource (123 pages)
附註:	Source: Dissertations Abstracts International, Volume: 85-07, Section: B.
Contained By:	Dissertations Abstracts International85-07B.
標題:	Chemistry. -
電子資源:	click for full text (PQDT)
ISBN:	9798381379730

A Chemical Biology Approach to the Cell Type Selective Killing of Glioblastoma Tumor Cells.
West, Thomas.

A Chemical Biology Approach to the Cell Type Selective Killing of Glioblastoma Tumor Cells. - 1 online resource (123 pages)

Source: Dissertations Abstracts International, Volume: 85-07, Section: B.

Thesis (Ph.D.)--The Scripps Research Institute, 2024.

Includes bibliographical references

Glioblastoma (GBM) remains virtually incurable; nearly all patients experience tumor progression with a median survival rate of less than 15 months1 . GBM's aggressive infiltration of the brain has been attributed to a specific sub population of cells termed cancer stem-like cells (CSC). Previously, the Lairson Lab identified a small molecule, RIPGBM, capable of driving GBM CSCs into apoptosis in a cell-type selective manner. The selectivity was proposed to derive from a unique pro-drug activation mechanism in which the molecule cyclized into an active derivative termed cRIPGBM which was found to be selectively formed in GBM CSCs. The molecular target of cRIPGBM was identified as Receptor Interacting Protein Kinase 2 (RIPK2)2 . Based on its structural similarity, the clinically used drug YM155 was subsequently evaluated for its ability bind RIPK2. This prompted the hypothesis that small molecule prodrugs that target RIPK2 are selectively activated in the tumor microenvironment, lead to cell type selective induction of apoptosis in GBM CSC's, and inhibit tumor growth in relevant rodent models.YM155 is a highly potent broad spectrum anti-cancer drug that was derived from a phenotypic screen for functional inhibitors of survivin expression, but for which the relevant biomolecular target remains unknown. Presumably as a result of its lack of cell type selectivity, YM155 has suffered from tolerability issues in the clinic. Based on its structural similarity to the GBM-selective prodrug RIPGBM, here, we report the design, synthesis, and characterization of a prodrug form of YM155, termed aYM155. aYM155 displays potent cell killing activity against a broad panel of patient-derived GBM cancer stem-like cells (IC50 = 0.7-10 nM), as well as EGFR-amplified and EGFR variant III-expressing (EGFRvIII) cell lines (IC50 = 3.8-36 nM), and becomes activated in a cell type-dependent manner. Mass spectrometry-based analysis indicates that enhanced cell type selectivity results from relative rates of prodrug activation in transformed versus non-transformed cell types. The prodrug strategy also facilitates transport into the brain (brain-to-plasma ratio, aYM155 = 0.56; YM155 = BLQ). In addition, we determine that the survivin-suppressing and apoptosis-inducing activities of YM155 involve its interaction with RIPK2. In an orthotopic intracranial GBM xenograft model, aYM155 prodrug significantly inhibits brain tumor growth in vivo, which correlates with cell type selective survivin-based pharmacodynamic effects.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2024

Mode of access: World Wide Web

ISBN: 9798381379730Subjects--Topical Terms:

593913
Chemistry.
Subjects--Index Terms:

GlioblastomaIndex Terms--Genre/Form:

554714
Electronic books.

A Chemical Biology Approach to the Cell Type Selective Killing of Glioblastoma Tumor Cells.
LDR:03999ntm a22004097 4500 001 1144966
005 20240617111729.5
006 m o d
007 cr mn ---uuuuu
008 250605s2024 xx obm 000 0 eng d
020 $a 9798381379730
035 $a (MiAaPQ)AAI30988457
035 $a AAI30988457
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a West, Thomas. $3 1470158
245 1 2 $a A Chemical Biology Approach to the Cell Type Selective Killing of Glioblastoma Tumor Cells.
264 0 $c 2024
300 $a 1 online resource (123 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 85-07, Section: B.
500 $a Advisor: Lairson, Luke L.;Erb, Michael A.
502 $a Thesis (Ph.D.)--The Scripps Research Institute, 2024.
504 $a Includes bibliographical references
520 $a Glioblastoma (GBM) remains virtually incurable; nearly all patients experience tumor progression with a median survival rate of less than 15 months1 . GBM's aggressive infiltration of the brain has been attributed to a specific sub population of cells termed cancer stem-like cells (CSC). Previously, the Lairson Lab identified a small molecule, RIPGBM, capable of driving GBM CSCs into apoptosis in a cell-type selective manner. The selectivity was proposed to derive from a unique pro-drug activation mechanism in which the molecule cyclized into an active derivative termed cRIPGBM which was found to be selectively formed in GBM CSCs. The molecular target of cRIPGBM was identified as Receptor Interacting Protein Kinase 2 (RIPK2)2 . Based on its structural similarity, the clinically used drug YM155 was subsequently evaluated for its ability bind RIPK2. This prompted the hypothesis that small molecule prodrugs that target RIPK2 are selectively activated in the tumor microenvironment, lead to cell type selective induction of apoptosis in GBM CSC's, and inhibit tumor growth in relevant rodent models.YM155 is a highly potent broad spectrum anti-cancer drug that was derived from a phenotypic screen for functional inhibitors of survivin expression, but for which the relevant biomolecular target remains unknown. Presumably as a result of its lack of cell type selectivity, YM155 has suffered from tolerability issues in the clinic. Based on its structural similarity to the GBM-selective prodrug RIPGBM, here, we report the design, synthesis, and characterization of a prodrug form of YM155, termed aYM155. aYM155 displays potent cell killing activity against a broad panel of patient-derived GBM cancer stem-like cells (IC50 = 0.7-10 nM), as well as EGFR-amplified and EGFR variant III-expressing (EGFRvIII) cell lines (IC50 = 3.8-36 nM), and becomes activated in a cell type-dependent manner. Mass spectrometry-based analysis indicates that enhanced cell type selectivity results from relative rates of prodrug activation in transformed versus non-transformed cell types. The prodrug strategy also facilitates transport into the brain (brain-to-plasma ratio, aYM155 = 0.56; YM155 = BLQ). In addition, we determine that the survivin-suppressing and apoptosis-inducing activities of YM155 involve its interaction with RIPK2. In an orthotopic intracranial GBM xenograft model, aYM155 prodrug significantly inhibits brain tumor growth in vivo, which correlates with cell type selective survivin-based pharmacodynamic effects.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2024
538 $a Mode of access: World Wide Web
650 4 $a Chemistry. $3 593913
650 4 $a Cellular biology. $3 1148666
650 4 $a Oncology. $3 593951
650 4 $a Biochemistry. $3 582831
653 $a Glioblastoma
653 $a Receptor Interacting Protein Kinase 2
653 $a Cancer stem-like cells
653 $a Pharmacodynamic effects
653 $a Phenotypic screen
655 7 $a Electronic books. $2 local $3 554714
690 $a 0485
690 $a 0379
690 $a 0992
690 $a 0487
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a The Scripps Research Institute. $b Chemical Biology. $3 1470159
773 0 $t Dissertations Abstracts International $g 85-07B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30988457 $z click for full text (PQDT)